| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100 - 1/500 | Human,Mouse,Rat |
| ICC | 1/50 - 1/500 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FCC1; COCA1; HNPCC; LCFS2 |
| Entrez GeneID | 4436 |
| clone | 1B3A8A8 |
| WB Predicted band size | 105kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human MSH2 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MSH2抗体的3篇代表性文献的简要信息：
1. **文献名称**：*Immunohistochemistry versus Microsatellite Instability Testing in Phenotypic Identification of Lynch Syndrome*
**作者**：Shia J, et al.
**摘要**：该研究比较了免疫组化(使用MSH2、MLH1等抗体)与微卫星不稳定性检测在筛查Lynch综合征中的效能，表明MSH2抗体缺失与基因突变高度相关，可作为临床筛选工具。
2. **文献名称**：*Mutations of the MSH2 Gene in Human Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome)*
**作者**：Leach FS, et al.
**摘要**：早期研究通过Western blot和免疫组化分析，证实MSH2基因突变导致蛋白表达缺失，建立了MSH2抗体作为遗传性结直肠癌分子诊断标志物的基础。
3. **文献名称**：*Validation of a Novel Antibody for Detection of MSH2 Protein Defects in Mismatch Repair-deficient Tumors*
**作者**：Hendriks YMC, et al.
**摘要**：研究验证了一种新型MSH2抗体的特异性与敏感性，发现其能可靠识别错配修复缺陷肿瘤中的蛋白表达异常，支持其在病理诊断中的应用。
如需更详细文献或近年研究，可进一步补充说明。
The MSH2 antibody is a crucial tool in molecular pathology and cancer research, primarily used to detect the MSH2 protein, a key component of the DNA mismatch repair (MMR) system. The MMR pathway corrects errors during DNA replication, and defects in MSH2—often due to genetic mutations—disrupt this process, leading to microsatellite instability (MSI) and increased cancer risk. Inherited MSH2 mutations are linked to Lynch syndrome, a hereditary condition predisposing individuals to colorectal, endometrial, and other cancers.
In clinical diagnostics, MSH2 antibodies are employed in immunohistochemistry (IHC) to assess protein expression in tumor tissues. Loss of MSH2 staining, alongside other MMR proteins (e.g., MLH1. PMS2. MSH6), helps identify MMR-deficient tumors, guiding Lynch syndrome testing and informing prognosis. MSH2-deficient tumors may respond differently to therapies, such as immune checkpoint inhibitors, which show efficacy in MSI-high cancers.
Researchers also use MSH2 antibodies to study DNA repair mechanisms, genetic instability, and tumorigenesis in experimental models. These antibodies enable functional analyses, including Western blotting and immunofluorescence, to explore MSH2 interactions within the MMR complex. Quality validation of MSH2 antibodies is critical, as variability in specificity can impact diagnostic accuracy. Overall, MSH2 antibodies bridge basic research and clinical practice, advancing precision oncology and hereditary cancer management.
×
